Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering boost treatments for human disease, obtained express results from a anew completed Phase 2 study of LX4211 in engagement with type 2 insulin-dependent insulin-dependent insulin-dependent diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small trifle drug seeker that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the gathering of glucose in the body and reducing caloric load.

More: - Brought to my attention by